Enforcement record
指定 disclosure naming 株式会社セルシード
This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.
Action type
指定
Law
Pharmaceutical Affairs Act
Authority
Ministry of Health, Labour and Welfare
Action date
28 February 2017
RegBase evidence report
Japanese public-record enforcement check
Saveable record of the published action, regulator source, source status, and review notes for internal compliance files.
- Report ID
- RB-EN-ENFORCEMENT-OTHER-SERUSIDO-20-202608041726
- Generated at
- 5 August 2026 at 02:26
- Record URL
- https://regbase.jp/en/enforcement/other-serusido-20170228
1. Review Summary
| Disclosure name | 株式会社セルシード | Corporate Number | Not stated in the disclosure |
|---|---|---|---|
| Enforcement record | 1 record | Other confirmed records for this company | Outside this report's scope |
| Action date | 28 February 2017 | Authority | Ministry of Health, Labour and Welfare |
| Law | Pharmaceutical Affairs Act | Action type | 指定 |
| Source status | Preserved public-source archive recorded | ||
This report summarizes public Japanese government disclosure data held by RegBase. It is not a credit score, sanctions conclusion, legal opinion, or adverse-media determination. Confirm important decisions against the linked official Japanese source.
2. Published Information
| Published name | 株式会社セルシード |
|---|
3. Enforcement Record
| Target name in disclosure | 株式会社セルシード |
|---|---|
| Authority | Ministry of Health, Labour and Welfare (厚生労働省) |
| Law / action type | Pharmaceutical Affairs Act / 指定 |
| Action / announcement date | Action: 28 February 2017 / Announcement: 7 April 2026 |
| English summary | The product is a cell sheet cultured from the patient's own oral mucosal epithelial cells, intended to prevent stenosis and shorten the time to re-epithelialization after endoscopic submucosal dissection (ESD) for esophageal cancer. Two clinical studies in Japan (19 cases) have been conducted, showing promising results with a high non-stenosis rate of 64%. |
| Original Japanese text | 患者自身の口腔粘膜から採取した上皮細胞を培養した細胞シートであり、食道がんにおける広範囲内視鏡的粘膜下層剥離術（ESD）後の狭窄の抑制及び再上皮化までの日数の短縮目的とするものである。国内で2つの臨床研究（19例）が実施されており、高い有効性を示唆する結果（本品の使用による高い非狭窄率64％）が得られた。 |
| Official source | https://www.mhlw.go.jp/stf/houdou/0000153128.html |
| Source archive | https://kiroku.today/a/60d0baf7afhg2xrw |
| Extraction / evidence timestamps | Extracted: 25 April 2026 at 09:13 / Evidence checked: 25 April 2026 at 09:13 / Archive captured: 12 July 2026 at 16:04 |
4. Business Location and Permit Details
No additional structured business-location or permit fields are recorded for this disclosure.
5. Other Confirmed Records for This Company
This report covers the single government disclosure shown on this page.
Reviewer Notes
| Reviewer | Team / company | ||
|---|---|---|---|
| Review purpose | |||
| Additional notes | |||
- □ Official source URL or archived source was checked.
- □ Corporate Number, address, or other identifiers were reviewed to avoid confusing similarly named entities.
- □ This document is understood as a public-record evidence file, not a credit decision or legal opinion.
Current page: Enforcement record
This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.
Free report
Save the disclosure record naming 株式会社セルシード
Includes the published name, regulator, governing law, source links, archive status, and reviewer note fields for internal due-diligence files.
Preserved evidence by Kiroku
Review the preserved source for 株式会社セルシード
Open the preserved public source with its capture time, original artifact, available verification data, and downloadable evidence pack.
For developers: JSON integration details
You do not need this for normal browsing. Use it only when integrating this enforcement record into an internal tool or AI workflow.
Action summary
- Company
- 株式会社セルシードJapanese onlyOriginal: 株式会社セルシード
- Governing law
- Pharmaceutical Affairs Act薬事法
- Action type
- 指定指定
- Action date
- 28 February 2017
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
The product is a cell sheet cultured from the patient's own oral mucosal epithelial cells, intended to prevent stenosis and shorten the time to re-epithelialization after endoscopic submucosal dissection (ESD) for esophageal cancer. Two clinical studies in Japan (19 cases) have been conducted, showing promising results with a high non-stenosis rate of 64%.
Show original Japanese text
患者自身の口腔粘膜から採取した上皮細胞を培養した細胞シートであり、食道がんにおける広範囲内視鏡的粘膜下層剥離術（ESD）後の狭窄の抑制及び再上皮化までの日数の短縮目的とするものである。国内で2つの臨床研究（19例）が実施されており、高い有効性を示唆する結果（本品の使用による高い非狭窄率64％）が得られた。
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Japanese regulatory disclosure under Pharmaceutical Affairs Act.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Evidence pack
- Extracted at
- 2026-04-25T00:13:59.368+00:00
- Evidence checked
- 2026-04-25T00:13:59.368+00:00
- Archive captured
- 2026-07-12T07:04:22.527496+00:00
Show audit JSON
{
"record": {
"id": "c2e33dfb-6e30-46f1-bf14-45a97b3744de",
"url": "https://regbase.jp/en/enforcement/other-serusido-20170228",
"company_name_original": "株式会社セルシード",
"company_name_registry": null,
"corporate_number": null,
"law": {
"ja": "薬事法",
"en": "Pharmaceutical Affairs Act"
},
"action_type": {
"ja": "指定",
"en": "指定"
},
"authority": {
"ja": "厚生労働省",
"en": "Ministry of Health, Labour and Welfare"
}
},
"entity_match": {
"status": "unresolved",
"confidence": 60,
"method": "extracted_japanese_name",
"method_label": "Company name extracted from the Japanese public disclosure",
"notes": "The linked company profile has not been verified under the current identity policy."
},
"review": {
"status": "unreviewed",
"label": "Machine extracted"
},
"compliance_context": {
"severity": "Context needed",
"actionMeaning": "This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.",
"practicalNote": "Review the original Japanese source and determine relevance to your counterparty-risk workflow.",
"lawContext": "Japanese regulatory disclosure under Pharmaceutical Affairs Act."
},
"evidence": {
"recordUrl": "https://regbase.jp/en/enforcement/other-serusido-20170228",
"officialSourceUrl": "https://www.mhlw.go.jp/stf/houdou/0000153128.html",
"officialDocumentUrl": null,
"archiveUrl": "https://kiroku.today/a/60d0baf7afhg2xrw",
"archivedSourceUrl": "https://www.mhlw.go.jp/stf/houdou/0000153128.html",
"archiveCapturedAt": "2026-07-12T07:04:22.527496+00:00",
"extractedAt": "2026-04-25T00:13:59.368+00:00",
"translatedAt": "2026-05-01T07:03:44.147+00:00",
"evidenceCheckedAt": "2026-04-25T00:13:59.368+00:00",
"generatedAt": "2026-08-04T17:26:25.895Z"
},
"limitations": [
"RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
"English summaries are provided for reference. The original Japanese source is authoritative.",
"Possible or unresolved entity matches should be manually verified before use in a decision."
]
}The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.